跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
FOQUEST - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
FOQUEST
Authorized
STANDARD
FOQUEST
elvium life sciences
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
2d0871371f168c0d
Company
elvium life sciences
Type
Standard
Approval Details
Approval Id
2d0871371f168c0d
Drug Approval Canada Name
FOQUEST
Product Name
FOQUEST
Status
Marketed
Status Date
2020-09-08
Original Market Date
2017-12-14
Din
02470292
Drug Class
Human
Dosage Form
Capsule (Controlled Release)
Route Of Administration
Oral
Schedule
Schedule G (CDSA III)
Ahfs
28:20.32
Atc Original
N06BA04 METHYLPHENIDATE
Atc Name
n 06 ba 04
Aig Number
0107548014
Company Name
elvium life sciences
Company Address
310, 3381 Steeles Avenue East, Toronto, Ontario, Canada, M2H 3S7
Active Ingredients
METHYLPHENIDATE HYDROCHLORIDE
25 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
2d0871371f168c0d
Type
Standard
Back to Health Canada Approvals